Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Multi-centre Randomised Clinical Trial of Obinutuzumab Versus Corticosteroid and Cyclophosphamide in Primary Membranous Nephropathy (REMIT Trial).

NCT06120673 is registered in ClinicalTrials.gov with The University of Queensland as lead sponsor.

NCT NCT06120673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06120673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Multi-centre Randomised Clinical Trial of Obinutuzumab Versus Corticosteroid and Cyclophosphamide in Primary Membranous Nephropathy (REMIT Trial).
Lead sponsor
The University of Queensland
Phase
Phase 3
Overall status
Withdrawn
Start date
October 31, 2025
Completion date
January 31, 2028
Enrollment
0 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy